Atacama Therapeutics

Executive Summary

Atacama Therapeutics is a private, early-stage biotechnology company headquartered in Cambridge, Massachusetts, founded in 2018 by experienced life science professionals. The company is focused on developing novel small-molecule therapies for serious dermatological conditions, with its lead candidate AT-5214 targeting acne vulgaris—a disease with significant unmet medical need and limited recent regulatory approvals. Atacama is currently conducting a proof-of-concept trial for AT-5214, aiming to demonstrate clinical efficacy and safety in patients. As a pre-revenue, privately held entity with no disclosed funding rounds, the company remains in a critical development phase, relying on its scientific expertise and the potential of AT-5214 to address a large, underserved market. The success of this trial will be pivotal in determining the company's trajectory and ability to attract further investment or partnerships.

Upcoming Catalysts (preview)

• Q4 2026Proof-of-concept data for AT-5214 in acne vulgaris40% success
• Q2 2026Series A financing round60% success
• Q1 2027Licensing or partnership deal for AT-521425% success